Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

MLA

Lavaud, Pernelle, et al. “Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-Naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.” European Urology, vol. 73, no. 5, May 2018, pp. 696–703. EBSCOhost, https://doi.org/10.1016/j.eururo.2017.09.022.

APA

Lavaud, P., Gravis, G., Foulon, S., Joly, F., Oudard, S., Priou, F., Latorzeff, I., Mourey, L., Soulié, M., Delva, R., Krakowski, I., Laguerre, B., Théodore, C., Ferrero, J. M., Beuzeboc, P., Habibian, M., Rolland, F., Deplanque, G., Pouessel, D., … Fizazi, K. (2018). Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. European Urology, 73(5), 696–703. https://doi.org/10.1016/j.eururo.2017.09.022

Chicago

Lavaud, Pernelle, Gwenaëlle Gravis, Stéphanie Foulon, Florence Joly, Stéphane Oudard, Frank Priou, Igor Latorzeff, et al. 2018. “Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-Naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.” European Urology 73 (5): 696–703. doi:10.1016/j.eururo.2017.09.022.